Liponex Inc. (TSX:LPX), a biopharmaceutical
company specializing in developing advanced products related to High Density
Lipoprotein (HDL), often called "good cholesterol," today provided an update
on its preparations for its Phase I/II clinical trial of its lead compound
CRD5, being developed for the treatment of dyslipidemia and heart disease.
